Roquette expands plant-based excipient portfolio with Crest Cellulose acquisition
Crest Cellulose, an Indian excipient manufacturer, has been acquired by plant-based pharmaceutical excipient provider Roquette in a bid to increase the latter’s presence in the Asia Pacific region.
French provider of plant-based ingredients and pharmaceutical/nutraceutical excipients Roquette has announced their complete acquisition of Indian excipient manufacturer Crest Cellulose, expanding their capacity to meet global demand for plant-based excipients.
India’s pharmaceutical industry is one of the largest global providers of generic medicines at a time when the production of generics in the Asia Pacific region is increasing in general. The acquisition of Crest Cellulose is hoped to establish a reinforced presence for Roquette in India and Asia, while also providing a global network of pharmaceutical research, development, and innovation facilities.
Crest Cellulose is set to be smoothly integrated into Roquette’s existing rigorous quality standards, meeting all major international regulatory requirements for excipients produced at the facility. Such plant-based excipients include MICROCEL, a microcrystalline cellulose, and LYCATAB CT, a partially pregelatinized starch.
VP Roquette Pharma Solutions Paul Smaltz commented on the acquisition: “At Roquette, we believe true innovation can only be achieved in an environment where ingredient safety is completely assured... There’s no room for compromise or shortcuts when tackling the world’s greatest health challenges. The team at Crest Cellulose share our conviction that quality is king, always striving to optimize processes and redefine what’s possible in drug delivery. As a global leader in health and nutrition, we’re excited to harness our newly expanded capabilities to support our network of customers and partners in India, Asia, and the rest of the world.
The acquisition will also focus on protecting the health of the planet and sustainable practices, a core pillar of Roquette’s ethos in bringing about healthier futures. Crest Cellulose will become the latest recipient of the Greentech ‘Environmental Protection’ award, recognising the environmental efforts of companies respecting the planet and its natural resources. Smaltz added: “Adding Crest Cellulose to the Roquette family gives us an opportunity to expand the reach of our sustainable development initiatives underpinned by four key pillars – innovating, sourcing, biorefining, acting – to build a healthier tomorrow. For Crest Cellulose and its customers, this means sustainable development will become central to every operation – ensuring we deliver top quality solutions that champion people, the planet, and prosperity. Supporting our commitment to reducing greenhouse gas emissions by 25% between 2021 and 2030, plans are in motion to install an additional 0.5 megawatt solar panel to the 10 kilowatts already in place at the site. This investment is designed to provide renewable energy for decades to come.”
Source: Roquette Complete Acquisition of Crest Cellulose - Corporate Pharma| Roquette
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance